USFDA inspects Dahej facility, no observations issued: Ajanta Pharma
New Delhi: Drug firm Ajanta Pharma said the US health regulator has not made any observations after completion of inspection of its Dahej facility in Gujarat.
"Our formulation facility at Dahej was inspected by US FDA from July 23-27, 2018. At the end of the inspection, no Form 483 was issued to us," Ajanta Pharma said in a BSE filing.
US Food and Drug Administration (USFDA) issues Form 483 to a company's management after completion of inspection of its facility to notify regarding objectionable conditions.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd